QureBio announced that its independently developed Q-1801 project received the domestic CDE clinical trial approval notice on January 11, 2023. Previously, the project had received the FDA clinical approval. Q-1801 was developed by QureBio using its antibody engineering technology platform, which is the world's first bispecific antibody simultaneous targeting SIRPα And PD-L1. Q-1801 is also the second clinical application project of QureBio. So far, QureBio has obtained four IND approvals from China and United States.
About QureBio Ltd.
QureBio Ltd. is a clinical-stage biopharmaceutical company focusing on innovative biopharmaceuticals for urgent and unmet clinical needs, such as the treatment of refractory cancers, inflammation and other serious disorders. Founded by experienced scientists from the relevant fields, QureBio Ltd. has built up a series of proprietary technologies for engineered bio-macromolecules, including innovative platforms for bi-specific and tri-specific antibodies.